Trial Profile

A Phase 1, Open-Label, Dose-Escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 in Melanoma Patients Receiving Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 19 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Igrelimogene litadenorepvec (Primary) ; Igrelimogene litadenorepvec (Primary)
Indications Malignant melanoma
Focus Adverse reactions; First in man
Acronyms TUNINTIL
Sponsors TILT Biotherapeutics

13 May 2025 According to a TILT Biotherapeutics media release, company announced that it has raised USD 25.6 million (EUR 22.6 million) in a Series B financing, will support the development of this trial.
08 Mar 2024 Planned End Date changed from 1 Feb 2025 to 1 Dec 2024.
08 Mar 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com